Skip to main content
KAPA
NYSE Life Sciences

Kairos Q3 10-Q: Going Concern Warning, $3.1M Cash, Material Weakness Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.465
Mkt Cap
$1.536M
52W Low
$0.418
52W High
$7.28
52W Position info
11% above low
Off High info
94% below high
Rel. Volume
Market data snapshot near publication time

KAPA is trading near its 52-week low of $0.418 (11% above the low).

Summary

Kairos reported a $5.0 million nine-month net loss with $3.1 million of cash and repeated its going-concern warning, funding itself through continued ATM sales ($1.87 million in the quarter period, $1.56 million after). Disclosure controls were again found ineffective due to an unremediated material weakness.


Key Events · Earnings and Guidance · KAPA

  • Going Concern Doubt Reiterated

    Nine-month net loss of $5,026 thousand and $3,027 thousand of cash used in operations; management says existing cash may not fund planned expenses for at least the next 12 months.

  • Cash Position Thin at $3.1M

    Cash and cash equivalents were $3,125 thousand at September 30, 2026, down from $4,491 thousand at December 31, 2025.

  • ATM Is the Only Funding Source

    Raised $1,870 thousand gross from 752,947 ATM shares in the first nine months, plus $1,558 thousand from 957,599 shares after quarter-end; the $4,500 thousand ATM program and $30,000 thousand Helena equity line remain the funding backstop.

  • Material Weakness Still Unremediated

    Management concluded disclosure controls were not effective at September 30, 2026, citing insufficient segregation of duties and review procedures first disclosed in the 2025 10-K.


Analysis · KAPA · Life Sciences

Kairos holds $3.1 million of cash against a $5.0 million nine-month operating loss and $3.0 million of cash burned in operations, and management states plainly that existing cash may not fund planned spending for the next 12 months. Auditors already flagged going-concern doubt for 2025, so survival now rests entirely on selling stock: $1.87 million was raised through the ATM in the first nine months and another $1.56 million after quarter-end, each tranche diluting holders at prices far below the $10.35 weighted-average warrant strike. Layered on top, disclosure controls were again deemed not effective because of an unremediated segregation-of-duties material weakness, and a new risk factor notes NYSE American's $0.25 minimum price rule (effective July 1, 2027) allows immediate suspension with no cure period — a real threat for a stock trading near $0.47.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KAPA was trading at $0.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.42 to $7.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KAPA - Latest Insights

KAPA
Nov 03, 2026, 11:50 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4751
Real-time Price: $0.465 info
Change: -$0.0101 (-2%) info
Market Cap: $1.536M info